Drug · INHIBITOR of bacterial DNA gyrase (mec_id 1901, target CHEMBL2311224) and of topoisomerase IV (mec_id 8639, target CHEMBL2363076); direct_interaction and disease_efficacy true for both. ATC J01MA02/S03AA07/S01AE03/S02AA15; black_box_warning TRUE.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Neutropenic Fever · Acute Lymphoblastic Leukemia · Acute Myeloblastic Leukemia · Non Hodgkin Lymphoma
Enrolment: 120 · Results not recorded
Prostate Infections
Enrolment: 31 · Results not recorded
Non-Cystic Fibrosis Bronchiectasis
Enrolment: 95 · Results not recorded
Crohn's Disease
Enrolment: 59 · Results not recorded
Diabetic Foot Ulcers
Enrolment: 9 · Results not recorded
Pain, Postoperative · Root Resorption · Persistent Infection · Necrotic Pulp
Enrolment: 108 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Partial body X irradiation 8 to 16 Gy with head, forelimbs and thorax shielded, sparing about 40% of bone marrow, 300 kV at 70 cGy per minute
Ciprofloxacin delayed onset and lowered incidence of delayed gastrointestinal effects at 13 to 14 Gy but not above 14 Gy, and reduced weight gain in unirradiated controls.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
